Navigation Links
Genomic analysis of prostate cancer indicates best course of action after surgery
Date:7/29/2014

(PHILADELPHIA) There is controversy over how best to treat patients after they've undergone surgery for prostate cancer. Does one wait until the cancer comes back or provide men with additional radiation therapy to prevent cancer recurrence? Now, a new study from Thomas Jefferson University shows that a genomic tool can help doctors and patients make a more informed decision.

"We are moving away from treating everyone the same," says first author Robert Den, M.D., Assistant Professor of Radiation Oncology and Cancer Biology at Thomas Jefferson University. "Genomic tools are letting us gauge which cancers are more aggressive and should be treated earlier with radiation, and which ones are unlikely to benefit from additional therapy."

Although surgery for prostate cancer is meant to be curative, in some men, the cancer can regrow. Doctors have developed high risk criteria based on clinical factors, but these criteria are imperfect predictors of cancer returning, or recurrence. Only about 50 percent of high risk patients ever go on to develop metastases, raising the question of whether those who receive additional therapy are being overtreated.

In an attempt to better understand how to treat their patient population, researchers led by Drs. Den and Adam Dicker, M.D., Ph.D., Chairman of the Department of Radiation Oncology at Jefferson, together with other members of the Kimmel Cancer Center Genitourinary team including Dr. Leonard Gomella, Chairman of the Department of Urology, assessed whether a genomic test designed to predict prostate cancer metastasis could also predict which patients would most benefit from radiation treatment after surgery.

The test, called Decipher, from the genome diagnostics company GenomeDx, generates a gene signature from a patient's cancer tissue sample. Based on this signature, the test stratifies patients into high, intermediate and low risk for cancer recurrence and metastases.

The researchers tested the genomes from tumor samples of 139 patients who had received radiation therapy following prostate surgery at Jefferson. Using medical records, the researchers grouped the patients by the treatments they received after surgery, and matched their records to the results of the genomic analysis.

The genomic analysis correctly predicted outcomes. The patients with a high Decipher score were more likely to develop metastases than those with a low score. In addition, those with a high Decipher score who received radiation earlier had longer survival than those who did not receive radiation immediately after surgery. The results showed that patients treated with radiation after surgery maintained low PSA levels for twice as long than those who were not treated with radiation.

"Our analysis suggests that genomic analysis scores could be used, in concert with other diagnostic measures such as PSA testing, to help determine which patients would benefit from additional radiation therapy and more aggressive measures, and which are less likely to benefit," says Dr. Den.


'/>"/>

Contact: Edyta Zielinska
edyta.zielinska@jefferson.edu
215-955-5291
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. Following the genomic pathways to stop the spread of cancer
2. Genomic study of rare childrens cancer yields possible prognostic tool
3. Mayo, UCSF team discovers genomic variant that increases risk of brain tumors
4. Study identifies genes associated with genomic expansions that cause disease
5. $8.9 million NIH grant to study genomic link to premature heart disease
6. Edith Sanford Breast Cancer Foundation and TSRI partner in genomic breast cancer research
7. Molecular Genetics & Genomic Medicine: New open access journal launched by Wiley
8. Ontario Genomics Institute invests in stem cell technology at Tissue Regenerative Therapeutics
9. Study shows large-scale genomic testing feasible, impacts therapy
10. Stanford/Yale study gives insight into subtle genomic differences among our own cells
11. NIH grant moves pathologists to the forefront of genomic medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... Harrisburg, PA (PRWEB) , ... May 04, 2016 , ... ... Commonwealth recently convened in the state capitol for the annual “Hike to Harrisburg” advocacy ... Society (PATS) and The Winter Group, PATS lobby Group. The goal for the ...
(Date:5/3/2016)... (PRWEB) , ... May 04, 2016 , ... ... than 40 national and global construction firms representing the Construction Industry Safety Initiative ... joined forces with one purpose: to inspire everyone in the industry to be ...
(Date:5/3/2016)... ... May 03, 2016 , ... In April, Amerec launched a new website ... help find the best steam and sauna solutions. , First, the Amerec website has ... improvement brings all of the site’s features, especially the Steam Builder Tool , ...
(Date:5/3/2016)... Irvine, California (PRWEB) , ... May 03, 2016 ... ... of its innovative brainsalvation tool – a web application that helps people assess ... medical research, the brainsalvation™ web app will provide users a “Risk Reduction Score™” ...
(Date:5/3/2016)... NJ (PRWEB) , ... May 03, 2016 , ... ... BCBSNJ) today announced that it has been honored as one of the nation’s ... the 2016 InformationWeek Elite 100. Horizon received the recognition for technology achievements that ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... YORK , May 3, 2016 ... (MRI) Market Size, Share, Development, Growth and Demand Forecast ... Open), by Field Strength (High Field, Very High Field, ... Application (Brain, Head and Neck, Spine, Musculoskeletal, Vascular, Breast, ... the global magnetic resonance imaging (MRI) market was valued ...
(Date:5/3/2016)... 3, 2016 Global and ... a basic overview of the industry that covers ... surgical mesh report explores into the international and ... report on Surgical Mesh market spread across 150 ... and figures is available at http://www.reportsnreports.com/reports/470569-global-and-chinese-surgical-mesh-industry-2016-market-research-report.html ...
(Date:5/2/2016)... 2016  Deerfield announced today it led the ... Inc. Graybug Vision is an early stage pharmaceutical ... care for ocular diseases including wet age-related macular ... first developed at Johns Hopkins University and has ... Graybug Vision is developing ophthalmology products ...
Breaking Medicine Technology: